<!doctype html><html lang=en><head><meta charset=utf-8><meta name=description content="Macrodantin, Furadantin, Macrobid
sage and Dosing
 Nitrofurantoin is used to treat uncomplicated lower urinary tract infections (UTI), e.g., cystitis, urethritis."><title>nitrofurantoin</title><meta name=viewport content="width=device-width,initial-scale=1"><link rel="shortcut icon" type=image/png href=https://htlin222.github.io/garden//icon.png><link href=https://htlin222.github.io/garden/styles.547fb332ce56cdc523146ba5ede80d7f.min.css rel=stylesheet><link href=https://htlin222.github.io/garden/styles/_light_syntax.86a48a52faebeaaf42158b72922b1c90.min.css rel=stylesheet id=theme-link><script src=https://htlin222.github.io/garden/js/darkmode.f852e6b434606ed577a6f145a9173070.min.js></script>
<script src=https://htlin222.github.io/garden/js/util.6f22941e242efae60fd84e7c32e874fa.min.js></script>
<link rel=preload href=https://cdn.jsdelivr.net/npm/katex@0.15.1/dist/katex.min.css as=style onload='this.onload=null,this.rel="stylesheet"' integrity=sha384-R4558gYOUz8mP9YWpZJjofhk+zx0AS11p36HnD2ZKj/6JR5z27gSSULCNHIRReVs crossorigin=anonymous><script defer src=https://cdn.jsdelivr.net/npm/katex@0.15.1/dist/katex.min.js integrity=sha384-z1fJDqw8ZApjGO3/unPWUPsIymfsJmyrDVWC8Tv/a1HeOtGmkwNd/7xUS0Xcnvsx crossorigin=anonymous></script>
<script defer src=https://cdn.jsdelivr.net/npm/katex@0.15.1/dist/contrib/auto-render.min.js integrity=sha384-+XBljXPPiv+OzfbB3cVmLHf4hdUFHlWNZN5spNQ7rmHTXpd7WvJum6fIACpNNfIR crossorigin=anonymous></script>
<script defer src=https://cdn.jsdelivr.net/npm/katex@0.16.2/dist/contrib/copy-tex.min.js integrity=sha384-ww/583aHhxWkz5DEVn6OKtNiIaLi2iBRNZXfJRiY1Ai7tnJ9UXpEsyvOITVpTl4A crossorigin=anonymous></script>
<script async src=https://unpkg.com/@floating-ui/core@0.7.3></script>
<script async src=https://unpkg.com/@floating-ui/dom@0.5.4></script>
<script async src=https://htlin222.github.io/garden/js/popover.f03552ccb84d99ca615d1cfb9abde59e.min.js></script>
<script defer src=https://htlin222.github.io/garden/js/code-title.ce4a43f09239a9efb48fee342e8ef2df.min.js></script>
<script defer src=https://htlin222.github.io/garden/js/clipboard.2913da76d3cb21c5deaa4bae7da38c9f.min.js></script>
<script defer src=https://htlin222.github.io/garden/js/callouts.7723cac461d613d118ee8bb8216b9838.min.js></script>
<script>const SEARCH_ENABLED=!1,LATEX_ENABLED=!0,PRODUCTION=!0,BASE_URL="https://htlin222.github.io/garden/",fetchData=Promise.all([fetch("https://htlin222.github.io/garden/indices/linkIndex.dc7ca1c57c2927f79a8c7dd15d8af8ff.min.json").then(e=>e.json()).then(e=>({index:e.index,links:e.links})),fetch("https://htlin222.github.io/garden/indices/contentIndex.7d15195e0e9164411a2273757d61341e.min.json").then(e=>e.json())]).then(([{index:e,links:t},n])=>({index:e,links:t,content:n})),render=()=>{const e=new URL(BASE_URL),t=e.pathname,n=window.location.pathname,s=t==n;addCopyButtons(),addTitleToCodeBlocks(),addCollapsibleCallouts(),initPopover("https://htlin222.github.io/garden",!0);const o=document.getElementById("footer");if(o){const e=document.getElementById("graph-container");if(!e)return requestAnimationFrame(render);e.textContent="";const t=s&&!1;drawGraph("https://htlin222.github.io/garden",t,[{"/moc":"#4388cc"}],t?{centerForce:1,depth:-1,enableDrag:!0,enableLegend:!1,enableZoom:!0,fontSize:.5,linkDistance:1,opacityScale:3,repelForce:1,scale:1.4}:{centerForce:1,depth:1,enableDrag:!0,enableLegend:!1,enableZoom:!0,fontSize:.6,linkDistance:1,opacityScale:3,repelForce:2,scale:1.2})}var i=document.getElementsByClassName("mermaid");i.length>0&&import("https://unpkg.com/mermaid@9/dist/mermaid.esm.min.mjs").then(e=>{e.default.init()})},init=(e=document)=>{addCopyButtons(),addTitleToCodeBlocks(),renderMathInElement(e.body,{delimiters:[{left:"$$",right:"$$",display:!0},{left:"$",right:"$",display:!1}],macros:{'â€™':"'"},throwOnError:!1})}</script><script type=module>
    import { attachSPARouting } from "https:\/\/htlin222.github.io\/garden\/js\/router.9d4974281069e9ebb189f642ae1e3ca2.min.js"
    attachSPARouting(init, render)
  </script></head><body><div id=search-container><div id=search-space><input autocomplete=off id=search-bar name=search type=text aria-label=Search placeholder="Search for something..."><div id=results-container></div></div></div><script src=https://cdn.jsdelivr.net/npm/flexsearch@0.7.21/dist/flexsearch.bundle.js integrity="sha256-i3A0NZGkhsKjVMzFxv3ksk0DZh3aXqu0l49Bbh0MdjE=" crossorigin=anonymous defer></script>
<script defer src=https://htlin222.github.io/garden/js/full-text-search.e6e2e0c213187ca0c703d6e2c7a77fcd.min.js></script><div class=singlePage><header><h1 id=page-title><a href=https://htlin222.github.io/garden/>èœ¥èœ´èŠ±åœ’ðŸ¦ŽðŸŒ±ðŸª´ðŸŒ²</a></h1><div class=spacer></div><div id=search-icon><p>Search</p><svg tabindex="0" aria-labelledby="title desc" role="img" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 19.9 19.7"><title id="title">Search Icon</title><desc id="desc">Icon to open search</desc><g class="search-path" fill="none"><path stroke-linecap="square" d="M18.5 18.3l-5.4-5.4"/><circle cx="8" cy="8" r="7"/></g></svg></div><div class=darkmode><input class=toggle id=darkmode-toggle type=checkbox tabindex=-1>
<label id=toggle-label-light for=darkmode-toggle tabindex=-1><svg xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" id="dayIcon" viewBox="0 0 35 35" style="enable-background:new 0 0 35 35"><title>Light Mode</title><path d="M6 17.5C6 16.672 5.328 16 4.5 16h-3C.672 16 0 16.672.0 17.5S.672 19 1.5 19h3C5.328 19 6 18.328 6 17.5zM7.5 26c-.414.0-.789.168-1.061.439l-2 2C4.168 28.711 4 29.086 4 29.5 4 30.328 4.671 31 5.5 31c.414.0.789-.168 1.06-.44l2-2C8.832 28.289 9 27.914 9 27.5 9 26.672 8.329 26 7.5 26zm10-20C18.329 6 19 5.328 19 4.5v-3C19 .672 18.329.0 17.5.0S16 .672 16 1.5v3C16 5.328 16.671 6 17.5 6zm10 3c.414.0.789-.168 1.06-.439l2-2C30.832 6.289 31 5.914 31 5.5 31 4.672 30.329 4 29.5 4c-.414.0-.789.168-1.061.44l-2 2C26.168 6.711 26 7.086 26 7.5 26 8.328 26.671 9 27.5 9zM6.439 8.561C6.711 8.832 7.086 9 7.5 9 8.328 9 9 8.328 9 7.5c0-.414-.168-.789-.439-1.061l-2-2C6.289 4.168 5.914 4 5.5 4 4.672 4 4 4.672 4 5.5c0 .414.168.789.439 1.06l2 2.001zM33.5 16h-3c-.828.0-1.5.672-1.5 1.5s.672 1.5 1.5 1.5h3c.828.0 1.5-.672 1.5-1.5S34.328 16 33.5 16zM28.561 26.439C28.289 26.168 27.914 26 27.5 26c-.828.0-1.5.672-1.5 1.5.0.414.168.789.439 1.06l2 2C28.711 30.832 29.086 31 29.5 31c.828.0 1.5-.672 1.5-1.5.0-.414-.168-.789-.439-1.061l-2-2zM17.5 29c-.829.0-1.5.672-1.5 1.5v3c0 .828.671 1.5 1.5 1.5s1.5-.672 1.5-1.5v-3C19 29.672 18.329 29 17.5 29zm0-22C11.71 7 7 11.71 7 17.5S11.71 28 17.5 28 28 23.29 28 17.5 23.29 7 17.5 7zm0 18c-4.136.0-7.5-3.364-7.5-7.5s3.364-7.5 7.5-7.5 7.5 3.364 7.5 7.5S21.636 25 17.5 25z"/></svg></label><label id=toggle-label-dark for=darkmode-toggle tabindex=-1><svg xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" id="nightIcon" viewBox="0 0 100 100" style="enable-background='new 0 0 100 100'"><title>Dark Mode</title><path d="M96.76 66.458c-.853-.852-2.15-1.064-3.23-.534-6.063 2.991-12.858 4.571-19.655 4.571C62.022 70.495 50.88 65.88 42.5 57.5 29.043 44.043 25.658 23.536 34.076 6.47c.532-1.08.318-2.379-.534-3.23-.851-.852-2.15-1.064-3.23-.534-4.918 2.427-9.375 5.619-13.246 9.491-9.447 9.447-14.65 22.008-14.65 35.369.0 13.36 5.203 25.921 14.65 35.368s22.008 14.65 35.368 14.65c13.361.0 25.921-5.203 35.369-14.65 3.872-3.871 7.064-8.328 9.491-13.246C97.826 68.608 97.611 67.309 96.76 66.458z"/></svg></label></div></header><article><h1>nitrofurantoin</h1><p class=meta>Last updated
Jan 15, 2023
<a href=https://github.com/htlin222/garden/tree/hugo/content/nitrofurantoin.md rel=noopener>Edit Source</a></p><ul class=tags></ul><p>Macrodantin, Furadantin, Macrobid</p><p>sage and Dosing</p><ul><li>Nitrofurantoin is used to treat uncomplicated lower urinary tract infections (UTI), e.g., cystitis, urethritis.</li><li>Not effective for infections outside of the urinary tract.</li><li>Because nitrofurantoin is a weak acid with a pKa of 7.2, absorption is enhanced in an acidic environment. Renal clearance is enhanced in an alkaline environment (
<a href=https://pubmed-ncbi-nlm-nih-gov.autorpa.kfsyscc.org/3291373/ rel=noopener>Urology 1988;32:67</a>).</li><li>Increased activity in acidic urine.</li><li>Original capsules contain microcrystals of nitrofurantoin, marketed in US as Furadantin. To decrease frequency of nausea, the drug was later formulated in macrocrystalline form (marketed as Macrodantin). Subsequently a slow release formulation was developed (25% macrocrystals, 75% monohydrate), marketed as Macrobid. As the name implies, administered bid.</li><li>Long-standing admonition to not use in patients with CrCl &lt;50-60 mL/min for fear of inadequate urine concentrations and/or increased adverse effects. However, in retrospective study, there was no difference in the safety and efficacy of nitrofurantoin in patients with CrCl â‰¤50 mL/min or CrCl >50 mL/min. <strong>Current American Geriatric Society recommendation is that nitrofurantoin can be used with relative safety and efficacy in patients with CrCl >30 mL/min</strong>
<a href=https://pubmed-ncbi-nlm-nih-gov.autorpa.kfsyscc.org/30693946/ rel=noopener>(J Am Geriatr Soc 67:674, 2019)</a>. Not effective in end-stage renal disease.</li><li>Pregnancy risk and lactation safety<ul><li><strong>Contraindicated</strong> in pregnant patients at term (38 to 42 weeks gestation), during labor and delivery, or when the onset of labor is imminent (the drug can cause hemolytic anemia in the newborn). For the same reason, the drug is contraindicated in neonates under one month of age.</li><li>See [Table](
<a href=https://webedition-sanfordguide-com.autorpa.kfsyscc.org/en/comparisons-1/pregnancy rel=noopener>https://webedition-sanfordguide-com.autorpa.kfsyscc.org/en/comparisons-1/pregnancy</a> risk lactation safety).</li></ul></li><li>Systematic Review:
<a href="http://www-ncbi-nlm-nih-gov.autorpa.kfsyscc.org:2048/pubmed?term=%22The+Journal+of+antimicrobial+chemotherapy%22%5BJour%5D+AND+70%5Bvolume%5D+AND+2456%5Bpage%5D&cmd=detailssearch" rel=noopener>J Antimicrob Chemother 70:2456, 2015</a></li></ul><p>se</p><table><tbody><tr><td>Active UTI</td><td>(Furadantin or Macrodantin) 50-100 mg po qid x 5-7 days or for at least 3 days after sterile urine achieved</td></tr><tr><td>&nbsp;</td><td>(Macrobid) 100 mg po bid x 5-7 days</td></tr><tr><td>UTI Prophylaxis</td><td>(Furadantin or Macrodantin) 50-100 mg po at bedtime</td></tr></tbody></table><p>se</p><ul><li>Age > 28 days</li></ul><table><tbody><tr><td>Oral dose: Cystitis</td><td>5-7 mg/kg/day (divided q 6h)</td></tr><tr><td>Oral Dose: UTI prophylaxis</td><td>1-2 mg/kg/day (once daily)</td></tr></tbody></table><p>stment</p><ul><li>CrCl >50 mL/min: Give usual dose</li><li>CrCl &lt;50 mL/min: See comment</li></ul><p>stment</p><ul><li>None</li></ul><p>se Effects</p><ul><li>Rare but serious liver injury.</li><li>Peripheral neuropathy can occur.</li><li>May impart a brown color to the urine.</li><li>Interstitial pneumonitis with progressive fibrosis can occur, usually after 6 months of therapy.</li><li>Hemolytic anemia if G6PD-deficient.</li><li>DRESS syndrome: Drug rash, eosinophilia, systemic symptoms hypersensitivity syndrome reported (
<a href="http://www-ncbi-nlm-nih-gov.autorpa.kfsyscc.org:2048/pubmed?term=%22The+Netherlands+journal+of+medicine%22%5BJour%5D+AND+67%5Bvolume%5D+AND+147%5Bpage%5D&cmd=detailssearch" rel=noopener>Neth J Med 67:147, 2009</a>).</li><li>In retrospective study, Nitrofurantoin was associated with increased risk of birth defects (
<a href="http://www-ncbi-nlm-nih-gov.autorpa.kfsyscc.org:2048/pubmed?term=%22Archives+of+pediatrics+%26+adolescent+medicine%22%5BJour%5D+AND+163%5Bvolume%5D+AND+978%5Bpage%5D&cmd=detailssearch" rel=noopener>Arch Ped Adol Med 163:978, 2009</a>); in contrast, subsequent study shows no risk of major malformations after exposure to Nitrofurantoin during the first trimester (
<a href=http://www-ncbi-nlm-nih-gov.autorpa.kfsyscc.org:2048/pubmed/23873250 rel=noopener>J Clin Pharmacol 53:991, 2013</a>).</li></ul><table><thead><tr><th>Class</th><th>Nitrofuran</th></tr></thead><tbody><tr><td>PK/PD Index</td><td>No data</td></tr><tr><td>&mdash;</td><td>&mdash;</td></tr><tr><td>Pharmaceutical</td><td></td></tr><tr><td>Preparation</td><td>Macrocrystalline cap (25, 50, 100 mg)</td></tr><tr><td>Oral susp (25 mg/5 ml)</td><td></td></tr><tr><td>Slow-release cap (100 mg)</td><td></td></tr><tr><td>&mdash;</td><td>&mdash;</td></tr><tr><td>Food Effect<sup>1</sup></td><td>Take all preps with food</td></tr><tr><td>Oral</td><td></td></tr><tr><td>Absorption<sup>2</sup> (%)</td><td>80-90</td></tr><tr><td>Tmax (hr)</td><td>No data</td></tr><tr><td>Peak Serum Conc<sup>3</sup></td><td></td></tr><tr><td>(Î¼g/mL)</td><td>&lt;1</td></tr><tr><td>Peak Urine Conc</td><td></td></tr><tr><td>(Î¼g/mL)</td><td>50-200 (100 mg, SD)</td></tr><tr><td>Protein Binding (%)</td><td>No data</td></tr><tr><td>Average Serum</td><td></td></tr><tr><td>Half-life<sup>4</sup> (hr)</td><td>0.5-2</td></tr><tr><td>Elimination</td><td>Renal, metabolism</td></tr><tr><td>Biliary Penetration<sup>5</sup> (%)</td><td>No data</td></tr><tr><td>CSF/Blood</td><td></td></tr><tr><td>Penetration<sup>6</sup> (%)</td><td>No data</td></tr><tr><td>Therapeutic Levels in CSF<sup>7</sup></td><td>No</td></tr><tr><td>Volume of Distribution<sup>8</sup></td><td></td></tr><tr><td>(Vd)</td><td>No data</td></tr><tr><td>AUC<sup>9</sup> (Î¼g*hr/mL)</td><td>1-3 (100 mg, 0-inf)</td></tr><tr><td>CYP450, Transporter Interactions</td><td>None known</td></tr></tbody></table><ul><li><p>Notes:</p><ul><li><p>SD = after single dose</p></li><li><p>SS = steady state after multiple doses</p></li><li><p>V/F = Vd/oral bioavailability</p></li><li><p>Vss = Vd at steady state</p></li><li><p>Vss/F = Vd at steady state/oral bioavailability</p></li></ul></li><li><p><sup>1</sup> Adult preparations unless otherwise noted.</p></li><li><p><sup>2</sup> Absorption under optimal conditions.</p></li><li><p><sup>3</sup> Total drug; adjust for protein binding to determine free drug concentration.</p></li><li><p><sup>4</sup> Assumes CrCl > 80 mL/min</p></li><li><p><sup>5</sup> Peak concentration in bile/peak concentration in serum x 100</p></li><li><p><sup>6</sup> CSF levels with inflammation</p></li><li><p><sup>7</sup> Judgment based on drug dose & organism susceptibility. CSF concentration ideally â‰¥10x above MIC.</p></li><li><p><sup>8</sup> Volume of Distribution (Vd):</p></li><li><p><sup>9</sup> Area under drug concentration curve (AUC)</p></li></ul><p>s</p><table><thead><tr><th>Drug</th><th>Effect on concentration</th><th>Â Suggested management</th></tr></thead><tbody><tr><td>Antacids</td><td>â†“ nitrofurantoin</td><td>Avoid co-administration</td></tr><tr><td>Probenecid</td><td>Â â†‘ nitrofurantoin</td><td>Monitor or avoid</td></tr><tr><td>Sulfinpyrazone</td><td>Â â†‘ nitrofurantoin</td><td>Monitor or avoid</td></tr></tbody></table><p>s</p><ul><li>None
<a class="internal-link broken">inbox</a></li></ul></article><hr><div class=page-end id=footer><div class=backlinks-container><h3>Backlinks</h3><ul class=backlinks><li><a href=/garden/Other-antimicrobial-agents-of-Drug-fever/ data-ctx=nitrofurantoin data-src=/Other-antimicrobial-agents-of-Drug-fever class=internal-link>Other antimicrobial agents of Drug fever</a></li></ul></div><div><script async src=https://cdn.jsdelivr.net/npm/d3@6.7.0/dist/d3.min.js integrity="sha256-+7jaYCp29O1JusNWHaYtgUn6EhuP0VaFuswhNV06MyI=" crossorigin=anonymous></script><h3>Interactive Graph</h3><div id=graph-container></div><style>:root{--g-node:var(--secondary);--g-node-active:var(--primary);--g-node-inactive:var(--visited);--g-link:var(--outlinegray);--g-link-active:#5a7282}</style><script src=https://htlin222.github.io/garden/js/graph.2d9e48dbe7ea47c0ef1c58296ce14448.js></script></div></div><div id=contact_buttons><footer><p>Made by Hsieh-Ting Lin using <a href=https://github.com/jackyzha0/quartz>Quartz</a>, Â© 2023</p><ul><li><a href=https://htlin222.github.io/garden/>Home</a></li><li><a href=https://twitter.com/htlin222>Twitter</a></li><li><a href=https://github.com/htlin222>GitHub</a></li></ul></footer></div></div></body></html>